News & Events Events & Presentations American Association for Cancer Research (AACR) 2023: A next generation TEAD inhibitor with refined isoform specificity for superior safety & efficacy Apr 17, 2023 View Presentation → Oppenheimer 33rd Annual Healthcare Conference Mar 15, 2023 View Presentation → American Association for Cancer Research (AACR) Special Conference: Targeting RAS Mar 7, 2023 View Presentation → 34th EORTC-NCI-AACR Symposium Oct 27, 2022 View Presentation → Press Releases 2023 2022 2021 2020 2019 Sporos BioDiscovery Presents Preclinical Data on Next-Generation TEAD Inhibitor, SPR1-0117, at the American Association for Cancer Research (AACR) Annual Meeting 2023 Apr 17, 2023 Read More → Sporos BioDiscovery to Present Preclinical Findings on SPR1, a Next-Generation TEAD Inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting 2023 Mar 15, 2023 Read More → Sporos BioDiscovery to Present at the Oppenheimer 33rd Annual Healthcare Conference Mar 9, 2023 Read More → Sporos BioDiscovery Presents Preclinical Data on Differentiated TEAD Inhibitor Program, SPR1, at the 34th EORTC-NCI-AACR Symposium Oct 27, 2022 Read More → FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma Oct 27, 2022 Read More → Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Idiopathic Pulmonary Fibrosis May 26, 2022 Read More → Tvardi Therapeutics’ TTI-101 Receives Orphan Drug Designation for Hepatocellular Carcinoma Apr 21, 2022 Read More → Data Demonstrating Tvardi’s TTI-101 Overcomes Palbociclib Resistance in Metastatic Breast Cancer Models to be Presented at the 2022 Annual Meeting of the American Association for Cancer Research Apr 11, 2022 Read More → Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer Jan 12, 2022 Read More → Sporos Bioventures Announces Formation of Strategic Advisory Board Jan 11, 2022 Read More → Sporos Bioventures Appoints Dr. Rachel Humphrey to Board of Directors Jan 4, 2022 Read More → Sporos Bioventures Appoints Amit Rakhit, M.D. as Chief Executive Officer Sep 29, 2021 Read More → Tvardi Therapeutics Raises $74 Million in Series B Financing to Advance Clinical Programs Jun 24, 2021 Read More → Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing Jun 3, 2021 Read More → Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing May 25, 2021 Read More → Sporos Launches with $38.1 Million Series A Financing May 6, 2021 Read More → Nirogy Therapeutics to Present at AACR Annual Meeting 2021 Apr 7, 2021 Read More → JLABS @ TMC and Asylia Therapeutics on Navigating a Powerful Tool: The Human Immune System Feb 17, 2021 Read More → Nirogy Therapeutics Launches with $16.5 Million Series A Financing Jan 26, 2021 Read More → Tvardi Therapeutics Awarded “Most Promising” Company at the 2020 Texas Life Science Forum Dec 28, 2020 Read More → New Company Asylia Therapeutics Finalizes Exclusive Worldwide License Agreement Oct 9, 2020 Read More → Tvardi Therapeutics Announces Publication Demonstrating TTI-101 as a Therapeutic Option for Treatment-Resistant Breast Cancers Oct 4, 2020 Read More → Tvardi’s TTI-101 Receives $5 Million in Funding to Support Clinical Trials and Translational Research Jun 24, 2020 Read More → Asylia Therapeutics Moves into JLABS @TMC Jun 6, 2020 Read More → KRLD Radio Interview: Some Covid Survivors Face Long-Term Consequences Jun 3, 2020 Read More → CPRIT Awards $3 Million to Asylia Therapeutics May 11, 2020 Read More → Heat Shock Protein-70 (HSP70) is an Essential Component of Anti-Tumor Immunity May 2, 2020 Read More → Biotech on the Rise Jan 2, 2019 Read More →
